Unknown

Dataset Information

0

Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial.


ABSTRACT: BACKGROUND:Pyronaridine-artesunate is a novel artemisinin-based combination therapy. The efficacy and safety of pyronaridine-artesunate were compared with artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children. METHODS:This phase III open-label randomized controlled non-inferiority trial was conducted in Western Kenya. Children aged 6 months to???12 years with a bodyweight?>?5 kg and microscopically confirmed P. falciparum malaria were randomly assigned in a 1:1 ratio to orally receive pyronaridine-artesunate or artemether-lumefantrine, dosed according to bodyweight, for 3 days. RESULTS:Of 197 participants, 101 received pyronaridine-artesunate and 96 received artemether-lumefantrine. The day-28 adequate clinical and parasitological response in the per-protocol population, PCR-corrected for reinfections, was 98.9% (93/94, 95% CI 94.2-99.8) for pyronaridine-artesunate and 96.4% (81/84, 95% CI 90.0-98.8) for artemether-lumefantrine. Pyronaridine-artesunate was found to be non-inferior to artemether-lumefantrine: the treatment difference was 2.5% (95% CI -?2.8 to 9.0). Adverse events occurred in 41.6% (42/101) and 34.4% (33/96) of patients in the pyronaridine-artesunate group and the artemether-lumefantrine group, respectively. No participants were found to have alanine or aspartate aminotransferase levels?>?3 times the upper limit of normal. CONCLUSIONS:Pyronaridine-artesunate was well tolerated, efficacious and non-inferior to artemether-lumefantrine for the treatment of uncomplicated P. falciparum malaria in Kenyan children. Results are in line with previous reports and inclusion of pyronaridine-artesunate in paediatric malaria treatment programmes should be considered. This study is registered at clinicaltrials.gov under NCT02411994. Registration date: 8 April 2015. https://clinicaltrials.gov/ct2/show/NCT02411994?term=pyronaridine-artesunate&cond=Malaria&cntry=KE&rank=1.

SUBMITTER: Roth JM 

PROVIDER: S-EPMC5952621 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial.

Roth Johanna M JM   Sawa Patrick P   Makio Nicodemus N   Omweri George G   Osoti Victor V   Okach Selpha S   Choy Felix F   Schallig Henk D F H HDFH   Mens Pètra P  

Malaria journal 20180515 1


<h4>Background</h4>Pyronaridine-artesunate is a novel artemisinin-based combination therapy. The efficacy and safety of pyronaridine-artesunate were compared with artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children.<h4>Methods</h4>This phase III open-label randomized controlled non-inferiority trial was conducted in Western Kenya. Children aged 6 months to ≤ 12 years with a bodyweight > 5 kg and microscopically confirmed P. falciparum malaria were  ...[more]

Similar Datasets

| S-EPMC6159604 | biostudies-literature
| S-EPMC5987563 | biostudies-literature
| S-EPMC9209011 | biostudies-literature
| S-EPMC4448218 | biostudies-literature
| S-EPMC8565026 | biostudies-literature
| S-EPMC3566922 | biostudies-literature
| S-EPMC8487544 | biostudies-literature
| S-EPMC3413505 | biostudies-literature
| S-EPMC4318246 | biostudies-literature
| S-EPMC5785863 | biostudies-literature